318 related articles for article (PubMed ID: 32278036)
1. Metabolomics identified new biomarkers for the precise diagnosis of pancreatic cancer and associated tissue metastasis.
Luo X; Liu J; Wang H; Lu H
Pharmacol Res; 2020 Jun; 156():104805. PubMed ID: 32278036
[TBL] [Abstract][Full Text] [Related]
2. Tissue metabolomics identified new biomarkers for the diagnosis and prognosis prediction of pancreatic cancer.
Liu C; Qin H; Liu H; Wei T; Wu Z; Shang M; Liu H; Wang A; Liu J; Shang D; Yin P
Front Oncol; 2022; 12():991051. PubMed ID: 36119530
[TBL] [Abstract][Full Text] [Related]
3. Serum metabolomics differentiating pancreatic cancer from new-onset diabetes.
He X; Zhong J; Wang S; Zhou Y; Wang L; Zhang Y; Yuan Y
Oncotarget; 2017 Apr; 8(17):29116-29124. PubMed ID: 28418859
[TBL] [Abstract][Full Text] [Related]
4. Metabolic system alterations in pancreatic cancer patient serum: potential for early detection.
Ritchie SA; Akita H; Takemasa I; Eguchi H; Pastural E; Nagano H; Monden M; Doki Y; Mori M; Jin W; Sajobi TT; Jayasinghe D; Chitou B; Yamazaki Y; White T; Goodenowe DB
BMC Cancer; 2013 Sep; 13():416. PubMed ID: 24024929
[TBL] [Abstract][Full Text] [Related]
5. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
6. Metabolomics identifies serum and exosomes metabolite markers of pancreatic cancer.
Tao L; Zhou J; Yuan C; Zhang L; Li D; Si D; Xiu D; Zhong L
Metabolomics; 2019 May; 15(6):86. PubMed ID: 31147790
[TBL] [Abstract][Full Text] [Related]
7. LC-MS/MS and SWATH based serum metabolomics enables biomarker discovery in pancreatic cancer.
Xiong Y; Shi C; Zhong F; Liu X; Yang P
Clin Chim Acta; 2020 Jul; 506():214-221. PubMed ID: 32243985
[TBL] [Abstract][Full Text] [Related]
8. Untargeted LC-HRMS-Based Metabolomics for Searching New Biomarkers of Pancreatic Ductal Adenocarcinoma: A Pilot Study.
Ríos Peces S; Díaz Navarro C; Márquez López C; Caba O; Jiménez-Luna C; Melguizo C; Prados JC; Genilloud O; Vicente Pérez F; Pérez Del Palacio J
SLAS Discov; 2017 Apr; 22(4):348-359. PubMed ID: 27655283
[TBL] [Abstract][Full Text] [Related]
9. Metabolomic Detection Between Pancreatic Cancer and Liver Metastasis Nude Mouse Models Constructed by Using the PANC1-KAI1/CD
Wang S; Chen J; Li H; Qi X; Liu X; Guo X
Technol Cancer Res Treat; 2021; 20():15330338211045204. PubMed ID: 34605330
[No Abstract] [Full Text] [Related]
10. Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics.
Hirata Y; Kobayashi T; Nishiumi S; Yamanaka K; Nakagawa T; Fujigaki S; Iemoto T; Kobayashi M; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Yamada T; Honda K; Azuma T; Yoshida M
Clin Chim Acta; 2017 May; 468():98-104. PubMed ID: 28215548
[TBL] [Abstract][Full Text] [Related]
11. Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma.
LaConti JJ; Laiakis EC; Mays AD; Peran I; Kim SE; Shay JW; Riegel AT; Fornace AJ; Wellstein A
BMC Genomics; 2015; 16 Suppl 1(Suppl 1):S1. PubMed ID: 25923219
[TBL] [Abstract][Full Text] [Related]
12. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic cancer screening using a multiplatform human serum metabolomics system.
Sakai A; Suzuki M; Kobayashi T; Nishiumi S; Yamanaka K; Hirata Y; Nakagawa T; Azuma T; Yoshida M
Biomark Med; 2016 Jun; 10(6):577-86. PubMed ID: 27171159
[TBL] [Abstract][Full Text] [Related]
14. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
[TBL] [Abstract][Full Text] [Related]
15. Protein-metabolite panel for early-stage pancreatic cancer.
Burki TK
Lancet Oncol; 2018 Oct; 19(10):e512. PubMed ID: 30146244
[No Abstract] [Full Text] [Related]
16. Multiple tumor marker protein chip detection system in diagnosis of pancreatic cancer.
Liu F; Du F; Chen X
World J Surg Oncol; 2014 Nov; 12():333. PubMed ID: 25381564
[TBL] [Abstract][Full Text] [Related]
17. New combined microRNA and protein plasmatic biomarker panel for pancreatic cancer.
Yuan W; Tang W; Xie Y; Wang S; Chen Y; Qi J; Qiao Y; Ma J
Oncotarget; 2016 Nov; 7(48):80033-80045. PubMed ID: 27713117
[TBL] [Abstract][Full Text] [Related]
18. UHPLC-HRMS-based Multiomics to Explore the Potential Mechanisms and Biomarkers for Colorectal Cancer.
Wang X; Guan X; Tong Y; Liang Y; Huang Z; Wen M; Luo J; Chen H; Yang S; She Z; Wei Z; Zhou Y; Qi Y; Zhu P; Nong Y; Zhang Q
BMC Cancer; 2024 May; 24(1):644. PubMed ID: 38802800
[TBL] [Abstract][Full Text] [Related]
19. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer.
Luo G; Liu C; Guo M; Cheng H; Lu Y; Jin K; Liu L; Long J; Xu J; Lu R; Ni Q; Yu X
Ann Surg; 2017 Apr; 265(4):800-805. PubMed ID: 28267695
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
